Skip to content

Clinical study for the treatment of allergic rhinitis by intralymphatic allergen-specific immunotherapy

Clinical study for the treatment of Dust mites-induced allergic rhinitis by intralymphatic allergen-specific immunotherapy

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800018399
Enrollment
Unknown
Registered
2018-09-15
Start date
2018-10-01
Completion date
Unknown
Last updated
2018-09-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

allergic rhinitis

Interventions

Case series:Lymph nodes were injected with allergen extract

Sponsors

Department of Otolaryngology, ZhuJiang Hospital of Southern Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
6 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Patients with allergic rhinitis (2015 tianjin standard) were clinically diagnosed with a clear single allergy to dust mites, and were free from sinusitis, asthma, and aspirin intolerance; 2. No significant abnormalities prevital signs include breathing, heart rate, blood pressure, and body temperature were found in the intralymphatic allergen-specific immunotherapy; 3. Patients were not treated with systemic or local glucocorticoid therapy or antihistamine or immunotherapy within the last 1 month.

Exclusion criteria

Exclusion criteria: 1. Patients with respiratory inflammation, asthma or irreversible upper respiratory diseases; 2. Patients who are at great risk of using epinephrine in the treatment of systemic adverse reactions, such as hypertension, aneurysm and cardiovascular and cerebrovascular diseases; 3. Patients who have been on the use of ß-R blockers (including eye drops) or ACEI drugs; 4. Patients with a history of anaphylactic shock; 5. In patients with a history of acute upper respiratory tract infection within one week; 6. Those with a history of severe acute or chronic disease, inflammation and fever, active tuberculosis, multiple sclerosis, immunological diseases including autoimmune diseases, immunological diseases caused by antigen-antibody complexes, immune deficiency, etc.,malignant tumors, diabetes, liver disease, kidney disease, mental disease, etc. 7. Pregnant and lactating women or women who have a pregnancy plan; 8. Severe acute or chronic cardiovascular dysfunction; 9. Children under 5 years old were excluded from the clinical trial.

Design outcomes

Primary

MeasureTime frame
VAS;RQLQ;cell factor of nasal secreta;serum cell factor;

Countries

China

Contacts

Public ContactWen Zhong

Department of Otolaryngology, ZhuJiang Hospital of Southern Medical University

wenzhong60@163.com+86 13538760316

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026